- Home
- ZVSA vs ENVB Comparison
ZVSA vs ENVB Comparison
Compare ZVSA & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- ENVB
- Stock Information
- Founded
- ZVSA 2014
- ENVB 1994
- Country
- ZVSA United States
- ENVB United States
- Employees
- ZVSA N/A
- ENVB N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- ZVSA Health Care
- ENVB Health Care
- Exchange
- ZVSA Nasdaq
- ENVB Nasdaq
- Market Cap
- ZVSA 3.0M
- ENVB 3.1M
- IPO Year
- ZVSA N/A
- ENVB N/A
- Fundamental
- Price
- ZVSA $0.69
- ENVB $1.25
- Analyst Decision
- ZVSA
- ENVB Strong Buy
- Analyst Count
- ZVSA 0
- ENVB 1
- Target Price
- ZVSA N/A
- ENVB $10.00
- AVG Volume (30 Days)
- ZVSA 1.5M
- ENVB 184.2K
- Earning Date
- ZVSA 08-08-2025
- ENVB 08-11-2025
- Dividend Yield
- ZVSA N/A
- ENVB N/A
- EPS Growth
- ZVSA N/A
- ENVB N/A
- EPS
- ZVSA N/A
- ENVB N/A
- Revenue
- ZVSA N/A
- ENVB N/A
- Revenue This Year
- ZVSA N/A
- ENVB N/A
- Revenue Next Year
- ZVSA N/A
- ENVB N/A
- P/E Ratio
- ZVSA N/A
- ENVB N/A
- Revenue Growth
- ZVSA N/A
- ENVB N/A
- 52 Week Low
- ZVSA $0.47
- ENVB $1.01
- 52 Week High
- ZVSA $6.30
- ENVB $11.55
- Technical
- Relative Strength Index (RSI)
- ZVSA 53.43
- ENVB 44.83
- Support Level
- ZVSA $0.61
- ENVB $1.20
- Resistance Level
- ZVSA $0.73
- ENVB $1.35
- Average True Range (ATR)
- ZVSA 0.07
- ENVB 0.07
- MACD
- ZVSA 0.00
- ENVB 0.01
- Stochastic Oscillator
- ZVSA 36.53
- ENVB 38.89
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.